Antares Pharma second-one fourth total revenue increases 78 percent to $3.

By the end of 2009. Net loss per share decreased for the next quarter to $0.02 in 2010 2010 from $0.03 in ’09 2009, and decreased for the six month period to $0.04 in 2010 2010 from $0.07 in 2009 2009, primarily because of an increase in income and gross profit producing a reduced net loss, along with an increase in weighted standard common shares outstanding. At June 30, 2010, Antares had around $11.4 million in cash, compared to approximately $13.at December 31 6 million, 2009. The net decrease in cash and cash equivalents was approximately $2.1 million in the initial half of 2010, in comparison to a net decrease of $6.1 million in the 1st half of 2009.A new pilot research led by experts at Beth Israel Deaconess INFIRMARY suggests that the mind changes connected with meditation and tension reduction may play a significant function in slowing the progression of age-related cognitive disorders like Alzheimer's disease and other dementias. ‘We realize that around 50 % of individuals diagnosed with slight cognitive impairment – the intermediate stage between your expected declines of regular aging and the much more serious cognitive deterioration connected with dementia – may develop dementia within five years. And regrettably, we know there are no FDA approved medicines that may stop that progression,’ says first writer Rebecca Erwin Wells, MD, MPH, who conducted her research mainly because a fellow in Integrative Medication at Harvard and BIDMC Medical School.